Benzinga · Oct 1, 2026
United Therapeutics Stock Rises Following Federal Court Patent Victory Over Liquidia
Shares of United Therapeutics are rising Thursday following a federal court victory in its patent litigation against competitor Liquidia.
UT
NYSE · UTHR
United Therapeutics Corporation
Healthcare · Biotechnology
$549.16
Up+$16.38 (+3.07%)
Updated Oct 10, 2026, 7:05 PM
SID Score
7.8/10
Composite research score
Smart Money
58/100
Neutral
- Market cap
- 21.83B
- P/E ratio
- 16.83
- Dividend yield
- 0.00%
- 52-week range
- $409.07 – $609.35
- Volume
- 577.86K
- Avg. volume
- 627.5K
Price performance · UTHR
UTHR price history
1M range · 21 trading sessions · Daily adjusted prices
Prices through Oct 9, 2026
UTHR closed at $549.16 after 21 trading sessions, up 10.47% for the selected period.
- Last close
- $549.16
- Period change
- +10.47%
- Period low
- $472.21
- Period high
- $571.38
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 9, 2026 | $528.92 | $551.15 | $528.92 | $549.16 | 577.86K |
| Oct 8, 2026 | $545.00 | $545.00 | $524.79 | $532.78 | 1.44M |
| Oct 7, 2026 | $542.41 | $558.30 | $541.90 | $545.00 | 1.01M |
| Oct 6, 2026 | $537.19 | $546.16 | $527.33 | $541.62 | 1.21M |
| Oct 5, 2026 | $540.41 | $547.98 | $535.53 | $536.40 | 833.72K |
| Oct 2, 2026 | $570.00 | $577.02 | $541.27 | $541.70 | 1.12M |
| Oct 1, 2026 | $557.53 | $585.79 | $556.7632 | $571.38 | 1.69M |
| Sep 30, 2026 | $482.20 | $557.37 | $475.46 | $541.89 | 3.34M |
| Sep 29, 2026 | $485.54 | $487.62 | $471.34 | $481.47 | 439.87K |
| Sep 28, 2026 | $473.84 | $486.98 | $470.76 | $485.54 | 628.27K |
| Sep 25, 2026 | $474.04 | $479.97 | $470.40 | $475.45 | 472.45K |
| Sep 24, 2026 | $472.72 | $481.3175 | $468.97 | $472.21 | 585.52K |
| Sep 23, 2026 | $498.82 | $500.05 | $487.7325 | $489.42 | 433.4K |
| Sep 22, 2026 | $493.98 | $499.58 | $488.08 | $497.59 | 586.4K |
| Sep 21, 2026 | $497.70 | $497.70 | $491.255 | $493.10 | 1.19M |
| Sep 18, 2026 | $498.07 | $499.23 | $492.57 | $494.63 | 1.5M |
| Sep 17, 2026 | $501.49 | $503.325 | $492.59 | $497.27 | 1.45M |
| Sep 16, 2026 | $500.62 | $505.775 | $497.665 | $498.48 | 488.4K |
| Sep 15, 2026 | $505.44 | $507.15 | $498.85 | $500.35 | 1.6M |
| Sep 14, 2026 | $506.78 | $509.065 | $499.62 | $502.70 | 605.73K |
| Sep 11, 2026 | $505.60 | $508.675 | $496.18 | $497.11 | 573.36K |
Latest UTHR news
The latest Smart Investors Daily articles mentioning UTHR.
Stock researchCompany · Overview
Company
Market Activity
Research & News
UTHR research
Overview
Company profile and research snapshot.
Company profile
United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. In addition, it is developing a pipeline of projects that includes new indications and delivery devices for existing products and new products to treat PAH and other conditions.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- Buy
- Average target
- $539.83
- Implied upside
- —
- Analysts
- 21
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 8, 2026 | RBC Capital | Outperform | — |
| Oct 7, 2026 | Morgan Stanley | Equal-Weight | — |
| Oct 1, 2026 | BTIG | Buy | — |
| Sep 24, 2026 | Goldman Sachs | Sell | — |
| Aug 6, 2026 | RBC Capital | Outperform | — |
News briefing
No generated briefing is available yet.
Yahoo · Sep 25, 2026
United Therapeutics Maps 14 Launches, Fibrosis Growth and Xenokidney Ambitions
United Therapeutics (NASDAQ:UTHR) outlined plans to expand its pulmonary fibrosis, pulmonary hypertension and organ-manufacturing businesses at the Bernstein Healthcare Leaders and Disruptors Conference, with management describing a pipeline of 14 prospective product launches and continued share rep
ChartMill · Sep 24, 2026
United Therapeutics (NASDAQ:UTHR): A Growth-at-a-Reasonable-Price Candidate
United Therapeutics fits Peter Lynch's GARP filters with zero debt, strong ROE, and a PEG under 1, though revenue growth has slowed.
Benzinga · Sep 24, 2026
Goldman Sachs Initiates Coverage On United Therapeutics with Sell Rating, Announces Price Target of $321
Goldman Sachs analyst Andrea Newkirk initiates coverage on United Therapeutics (NASDAQ:UTHR) with a Sell rating and announces Price Target of $321.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
